7:08 am Omeros reports additional positive phase 1 clinical data for OMS824 for the treatment of cognitive disorders; PDE10 target engagement continues to increase with well-tolerated doses
View todays social media effects on OMER
View the latest stocks trending across Twitter. Click to view dashboard
See who Omeros is hiring next, click here to view
